Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities
05. Juni 2023 07:00 ET
|
Domain Therapeutics
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities DT-9045 is a unique drug candidate due to its competitive...
Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting
10. November 2022 09:00 ET
|
Domain Therapeutics
Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual MeetingData unveiled on clinical candidate EP4R antagonist, DT-9081, and CCR8 depleting-antibody...